Proven Results

Case Studies.

Real-world examples of how data-driven quality management reduces risk and improves efficiency.

CASE_STUDY_01Strategy Success

Reducing On-Site Monitoring by 30%

Client

Mid-sized Biotech (Phase II Oncology)

Challenge

100% SDV (Source Data Verification) was draining budget and not detecting critical errors.

Solution

Implemented Centralized Monitoring with targeted SDV based on site risk scores.

"We were drowning in travel costs. This approach didn't just save money; it helped us find the sites that actually needed help."

— Clinical Operations Leader, Mid-Sized Biotech

-30%

Reduction in on-site monitoring visits, saving approx. $450k in travel & resource costs.

Increase in critical finding detection rate compared to traditional CRA monitoring.

FIG 1.1: SITE RISK SCORE DISTRIBUTION

CASE_STUDY_02Enablement Success

Rescuing a Stalled CluePoints Implementation

Client

Global Pharma (Phase III CNS)

Challenge

Bought CluePoints but CRAs ignored the signals because they didn't understand the statistical flags.

Solution

Redesigned the "Signal Review Process" and conducted "Stats for Non-Statisticians" workshops.

"We had a Ferrari engine in a go-kart. You taught us how to actually drive the car. Adoption went from 10% to 95% in two months."

— Data Management Executive, Global Pharma

95%

User adoption rate achieved within 60 days of process re-engineering.

-60%

Reduction in "False Positive" signals by tuning thresholds to protocol specifics.

FIG 2.1: SIGNAL REVIEW COMPLIANCE

BEFORE12%

AFTER TRAINING95%

CASE_STUDY_03Tailored Solutions Success

Custom Safety Dashboard for Complex Oncology

Client

Top 10 CRO

Challenge

Standard EDC reports were missing delayed toxicity signals across multiple study arms.

Solution

Built a custom R-Shiny application integrating Lab, AE, and ConMed domains.

"The standard reports were useless for this protocol. Your dashboard is the first thing our Medical Monitors open every morning."

— Medical Affairs Leader, Top 10 CRO

SAFETY_SIGNAL_DETECTOR_V2.0

SIGNAL_ID: TOX-004CRITICAL

Identified a correlation between Study Drug Dose Level 3 and Grade 3 Neutropenia two weeks earlier than standard medical review.

Data Sources Integrated

Real-time

Data Refresh

100%

Audit Trail

CASE_STUDY_04Validation Success

CSA-Based Validation Cuts Timeline by 75%

Client

Top 20 Pharma (Global Operations)

Trial Scope

3 concurrent Phase III trials, 450+ sites, 12 countries

Challenge

Traditional CSV approach required 6+ months per platform validation. Three new RBQM tools needed validation simultaneously.

Solution

Implemented Computer Software Assurance (CSA) framework with risk-based test strategies. Focused scripted testing on GxP-critical features; used exploratory testing for low-risk areas.

"We validated three platforms in the time it used to take us to validate one. And we found more actual bugs because testers were thinking critically instead of following scripts."

— Head of Quality Systems, Top 20 Pharma

75%

Reduction in validation timeline (6 months to 6 weeks per platform)

87%

Reduction in documentation pages (1,200 to 150 pages per system)

+30%

Increase in actual defects found through exploratory testing

FIG 4.1: VALIDATION EFFORT COMPARISON (HOURS)

Traditional CSV Approach2,400 hrs

Scripted Testing: 70% | Documentation: 25% | Review: 5%

CSA Risk-Based Approach600 hrs

Critical: 40% | Exploratory: 40% | Docs: 20%

CASE_STUDY_05Strategy Success

Enterprise RBQM Rollout Across 8 Therapeutic Areas

Client

Top 5 Global Pharmaceutical Company

Trial Scope

42 active trials, 2,800+ sites, 35 countries

Challenge

Fragmented RBQM adoption: each therapeutic area had different processes, KRI definitions, and platform configurations. No enterprise-wide quality visibility.

Solution

Designed a unified RBQM framework with standardized KRI library, governance model, and cross-functional RBQM committee. Implemented phased rollout with therapeutic area champions.

"For the first time, our CMO can see quality metrics across every trial in our portfolio on a single dashboard. That visibility has fundamentally changed how we make resource allocation decisions."

— VP Clinical Operations, Top 5 Global Pharma

Trials onboarded to unified RBQM framework within 18 months

-46%

Reduction in audit findings across portfolio after RBQM standardization

$2.1M

Annual monitoring cost savings from optimized site visit scheduling

89%

CRA adoption rate of centralized monitoring workflows within 6 months

FIG 5.1: RBQM MATURITY BY THERAPEUTIC AREA (18-MONTH TRAJECTORY)

Oncology

25%90%

CNS

15%85%

Cardio

30%88%

Rare Disease

10%82%

Aggregate Impact

Results Across All Engagements

Anonymized aggregate data from consulting engagements spanning pharmaceutical sponsors, CROs, and technology vendors.

50+

RBQM Programs Designed

35%

Avg. Monitoring Cost Reduction

90%+

Avg. Platform Adoption Rate

Critical Audit Findings Post-RBQM

Case Studies.

Reducing On-Site Monitoring by 30%

Rescuing a Stalled CluePoints Implementation

Custom Safety Dashboard for Complex Oncology

SAFETY_SIGNAL_DETECTOR_V2.0

CSA-Based Validation Cuts Timeline by 75%

Enterprise RBQM Rollout Across 8 Therapeutic Areas

Results Across All Engagements

We value your privacy